Sanctuary Advisors LLC Buys Shares of 15,018 Moderna, Inc. $MRNA

Sanctuary Advisors LLC purchased a new position in shares of Moderna, Inc. (NASDAQ:MRNA) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 15,018 shares of the company’s stock, valued at approximately $1,052,000.

Several other hedge funds have also made changes to their positions in the business. Bank of Nova Scotia acquired a new position in shares of Moderna in the second quarter valued at approximately $542,000. Commerce Bank acquired a new stake in Moderna during the 2nd quarter worth approximately $3,869,000. Northwestern Mutual Wealth Management Co. acquired a new stake in Moderna during the 2nd quarter worth approximately $1,013,000. Quantbot Technologies LP purchased a new position in Moderna in the 2nd quarter valued at approximately $785,000. Finally, Evolve Private Wealth LLC purchased a new position in Moderna in the 2nd quarter valued at approximately $263,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Analyst Upgrades and Downgrades

MRNA has been the subject of several analyst reports. Bank of America raised Moderna from an “underperform” rating to a “neutral” rating in a research note on Wednesday, August 19th. William Blair raised Moderna from a “market perform” rating to an “outperform” rating in a research report on Wednesday, August 19th. Morgan Stanley lifted their price objective on Moderna from $39.00 to $89.00 and gave the company an “equal weight” rating in a research note on Thursday, August 20th. Brookline Capital Markets reissued a “buy” rating on shares of Moderna in a research report on Wednesday, August 19th. Finally, Piper Sandler reissued an “overweight” rating on shares of Moderna in a research report on Monday, August 3rd. Four equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Moderna has an average rating of “Hold” and a consensus price target of $74.31.

Insider Activity

In other news, insider Shannon Thyme Klinger sold 3,471 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $50.00, for a total transaction of $173,550.00. Following the sale, the insider owned 67,468 shares of the company’s stock, valued at approximately $3,373,400. This trade represents a 4.89% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 53,336 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $51.37, for a total value of $2,739,870.32. Following the sale, the president owned 1,483,848 shares of the company’s stock, valued at approximately $76,225,271.76. The trade was a 3.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 10.80% of the company’s stock.

Moderna Stock Performance

Shares of MRNA stock opened at $142.77 on Friday. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. The firm has a fifty day moving average price of $75.62 and a 200 day moving average price of $59.17. The company has a market cap of $57.00 billion, a P/E ratio of -17.87 and a beta of 0.91. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $176.66.

Moderna (NASDAQ:MRNA) last posted its earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, beating the consensus estimate of ($2.03) by $0.06. The firm had revenue of $145.00 million for the quarter, compared to analyst estimates of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.Moderna’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($2.13) earnings per share. Sell-side analysts predict that Moderna, Inc. will post -6.18 earnings per share for the current fiscal year.

Key Headlines Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: The FDA approved Moderna’s updated 2026–2027 Spikevax and mNEXSPIKE COVID-19 vaccines, which target the XFG subvariant. The approval supports Moderna’s ability to participate in the upcoming seasonal vaccination market, although Spikevax eligibility is focused on adults 65 and older and higher-risk people ages 6 months through 64. FDA approves updated COVID vaccines
• Positive Sentiment: Renewed attention on Moderna and Merck’s personalized cancer vaccine, intismeran, is supporting the company’s long-term oncology story. Reports indicate the therapy reduced melanoma recurrence by approximately 49% in a late-stage study, strengthening expectations that Moderna could diversify beyond its declining COVID-19 business. Personalized melanoma vaccine results
• Neutral Sentiment: Moderna announced plans to raise $2 billion through convertible senior notes due in 2032, with an option for purchasers to increase the deal to $2.3 billion. Proceeds may fund oncology investments and debt repayment, while a hedge overlay is intended to offset dilution up to a specified cap. Moderna convertible notes offering
• Negative Sentiment: Investors are reacting cautiously to the financing because convertible notes can create future share dilution and signal substantial funding needs. The offering comes while Moderna remains unprofitable, making the company’s elevated valuation more difficult to justify on current earnings and revenue. Moderna borrows $2 billion

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.